Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07537257) titled 'VEN+IDAC vs IDAC in AML' on April 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Second Provincial General Hospital
Condition:
AML (Acute Myelogenous Leukemia)
Intervention:
Drug: Ventoclax
Recruitment Status: Recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: April 1, 2026
Target Sample Size: 232
Countries of Recruitment:
China
To know more, visit https://clinicaltrials.gov/study/NCT07537257
Published by HT Digital Content Services with permission...